CytRx Corporation has received a patent covering for its tumour-targeting linker platform technology and pharmaceutical compositions from the European Patent Office (EPO).
The company also revealed aldoxorubucin as the new generic name for INNO-206, the conjugate which comprises the protein-binding linker technology, a chemotherapeutic drug doxorubicin.
CytRx president and CEO Steven A. Kriegsman said it is particularly exciting coming on the heels of our recent presentation at the American Society of Clinical Oncology (ASCO) conference of favourable results from our aldoxorubicin Phase 1b/2 clinical trial in patients with advanced sarcomas whose tumors had progressed after receiving other chemotherapies.
"The technology can be used with multiple chemotherapeutic agents, making it in effect its own potential drug pipeline with blockbuster possibilities," Kriegsman added.
CytRx holds rights to the single-molecule linker technology licensed from the Tumour Biology Institute in Freiburg, Germany.
CytRx is presently experimenting an international Phase 2b clinical trial comparing aldoxorubicin with native doxorubicin as a therapy in patients with soft tissue sarcomas.
